Sermorelin, Research Overview & Evidence

Overview

A truncated GHRH analog that stimulates the pituitary to release growth hormone, historically used in paediatric diagnostics.

Sermorelin is classified as a ghrh analog. Its current development status is: previously fda-approved; now compounded. Human trial data exists but is limited in size, duration or independence; conclusions should be held loosely.

The Peptide Institute tracks Sermorelin because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Sermorelin

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies: 4
Samples: 4
Updated: Aug 14, 2026

1 Research Peptides Co. Exceptional Institute
Top Rated Sermorelin
98.1% average purity across 1 sample
Purity & Testing 98 Transparency 84 Samples 1 90 View company
2 NextGen Peptides Excellent
98.5% average purity across 1 sample
Purity & Testing 91 Transparency 80 Samples 1 85 View company
3 Atlas Peptide Labs Excellent
98.2% average purity across 1 sample
Purity & Testing 99 Transparency 72 Samples 1 85 View company

Compare all tested Sermorelin companies

Research & Studies

Studies library

Comparative effects of Sermorelin on metabolic endpoints

Peptides · Randomized controlled trial (Phase 3) · Aug 19, 2023

Adds to the Sermorelin evidence base without resolving the central question of human efficacy.
Pharmacokinetics and tolerability of Sermorelin in healthy adults

Diabetes Care · Pharmacokinetic study (Phase 1) · Jan 29, 2015

Reports findings relevant to the primary claims made for Sermorelin; sample size limits how far the result generalises.